Actelion Pharmaceuticals Ltd: Actelion and GSK Discontinue Clinical Development of Almorexant

Actelion Pharmaceuticals Ltd / Actelion and GSK Discontinue Clinical Development of Almorexant Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND & LONDON, UK - 28 January 2011 - Actelion Ltd (SIX: ATLN) and GlaxoSmithKline (GSK) today announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued.  This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.

GSK and Actelion remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications.  Both companies will continue to work on the discovery and development of new orexin receptor antagonist therapies, based on the orexin alliance formed in July 2008.

 

###

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland.  Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension.  Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream.  Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).

 

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com (http://www.gsk.com/)

 

Actelion Enquiries:

Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
[phone]
[phone]
www.actelion.com (http://www.actelion.com/)

 

GlaxoSmithKline Enquiries:	Â	Â
UK Media enquiries:	David Mawdsley	[phone]
Â	Claire Brough	[phone]
Â	Stephen Rea	[phone]
Â	Alexandra Harrison	[phone]
Â	Jo Revill	[phone]
Â	Â	Â
US Media enquiries:	Nancy Pekarek	[phone]
Â	Mary Anne Rhyne	[phone]
Â	Kevin Colgan	[phone]
Â	Jennifer Armstrong	[phone]
Â	Â	Â
European Analyst/Investor enquiries:	Sally Ferguson	[phone]
Â	Gary Davies	[phone]
Â	Ziba Shamsi	[phone]
Â	Â	Â
US Analyst/ Investor enquiries:	Tom Curry	[phone]

 

 

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.

 

 

 

 

 

Press Release PDF (http://hugin.info/131801/R/1483135/418360.pdf)

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

HUG#1483135